Last updated: 11/07/2018 03:39:50

Clinical study in children, 6 months to 3 years of age, to assess two dose levels of an experimental flu vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control

GSK study ID
111635
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Clinical study in children, 6 months to 3 years of age, to assess the immunogenicity and safety of two dose levels of thimerosal-free Fluviral® vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control
Trial description: Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve their efficacy in infants. In this study, we will compare two different dose levels of GSK1557482A flu vaccine. Another already approved flu vaccine made by a different company will be used as a control.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Number of subjects with any and grade 3 solicited local symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related solicited general symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related unsolicited adverse events (AEs) after vaccination

Timeframe: During the 28-day follow-up period (Days 0-27) after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Secondary outcomes:

Titers for serum Hemagglutination Inhibition (HI) antibodies

Timeframe: At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]

Number of subjects seroconverted to HI antibodies

Timeframe: At Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Number of subjects seroprotected against HI antibodies

Timeframe: At Day 0 [PRE] and at Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Seroconversion factor for HI antibodies

Timeframe: At Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Number of subjects with any and grade 3 solicited local symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related solicited general symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related unsolicited adverse events (AEs) after vaccination

Timeframe: During the 28-day follow-up period (Days 0-27) after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 28-day post-vaccination period after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Interventions:
  • Biological/vaccine: GSK Biologicals’ influenza vaccine GSK1557482A
  • Biological/vaccine: Vaxigrip
  • Enrollment:
    390
    Primary completion date:
    2009-19-08
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Langley JM et al. (2012) Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: A randomized, controlled trial. J Pediatr Infect Dis Soc.1(1):55-63.
    Medical condition
    Influenza
    Product
    GSK1557482A
    Collaborators
    Not applicable
    Study date(s)
    November 2008 to August 2009
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    6 - 36 months
    Accepts healthy volunteers
    Yes
    • A male or female child 6 months to < 3 years of age at the time of the vaccination, regardless of previous administration of influenza vaccine in a previous season;
    • Subjects must be in good health established by medical history and physical examination before entering into the study;
    • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion;
    • History of hypersensitivity to any vaccine;

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Halifax, Nova Scotia, Canada, B3K 6R8
    Status
    Study Complete
    Location
    GSK Investigational Site
    Ste-Foy, Québec, Canada, G1X 3V7
    Status
    Study Complete
    Location
    GSK Investigational Site
    Sarnia, Ontario, Canada, N7T 4X3
    Status
    Study Complete
    Location
    GSK Investigational Site
    Winnipeg, Manitoba, Canada, R3E 3P4
    Status
    Study Complete
    Location
    GSK Investigational Site
    London, Ontario, Canada, N6H 4P2
    Status
    Study Complete
    Location
    GSK Investigational Site
    Mississauga, Ontario, Canada, L5A 3V4
    Status
    Study Complete
    Showing 1 - 6 of 18 Results

    Study documents

    Clinical study report
    Available language(s): English
    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2009-19-08
    Actual study completion date
    2009-19-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website